PURPOSE: To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer. METHODS AND MATERIALS: Patients with stage IIA-IVA esophageal or gastroesophageal junction cancer were enrolled in a Simon's two-stage phase II study. Patients received weekly cetuximab on weeks 0-8 and irinotecan and cisplatin on weeks 1, 2, 4, and 5, with concurrent radiotherapy (50.4 Gy on weeks 1-6), followed by surgical resection. RESULTS: In the first stage, 17 patients were enrolled, 16 of whom had adenocarcinoma. Because of a low pathologic complete response (pCR) rate in this cohort, the trial was discontinued for patients with adenocarcinoma but squamous cell carcinoma patients continued to be enrolled; two additional patients were enrolled before the study was closed as a result of poor accrual. Of the 19 patients enrolled, 18 patients proceeded to surgery, and 16 patients underwent an R0 resection. Three patients (16%) had a pCR. The median progression-free survival interval was 10 months, and the median overall survival duration was 31 months. Severe neutropenia occurred in 47% of patients, and severe diarrhea occurred in 47% of patients. One patient died preoperatively from sepsis, and one patient died prior to hospital discharge following surgical resection. CONCLUSIONS: This schedule of cetuximab in combination with irinotecan, cisplatin, and radiation therapy was toxic and did not achieve a sufficient pCR rate in patients with localized esophageal adenocarcinoma to undergo further evaluation.
PURPOSE: To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer. METHODS AND MATERIALS: Patients with stage IIA-IVA esophageal or gastroesophageal junction cancer were enrolled in a Simon's two-stage phase II study. Patients received weekly cetuximab on weeks 0-8 and irinotecan and cisplatin on weeks 1, 2, 4, and 5, with concurrent radiotherapy (50.4 Gy on weeks 1-6), followed by surgical resection. RESULTS: In the first stage, 17 patients were enrolled, 16 of whom had adenocarcinoma. Because of a low pathologic complete response (pCR) rate in this cohort, the trial was discontinued for patients with adenocarcinoma but squamous cell carcinomapatients continued to be enrolled; two additional patients were enrolled before the study was closed as a result of poor accrual. Of the 19 patients enrolled, 18 patients proceeded to surgery, and 16 patients underwent an R0 resection. Three patients (16%) had a pCR. The median progression-free survival interval was 10 months, and the median overall survival duration was 31 months. Severe neutropenia occurred in 47% of patients, and severe diarrhea occurred in 47% of patients. One patient died preoperatively from sepsis, and one patient died prior to hospital discharge following surgical resection. CONCLUSIONS: This schedule of cetuximab in combination with irinotecan, cisplatin, and radiation therapy was toxic and did not achieve a sufficient pCR rate in patients with localized esophageal adenocarcinoma to undergo further evaluation.
Authors: Jennifer J Knox; Rebecca Wong; Antonio L Visbal; Anne M Horgan; Maha Guindi; Jennifer Hornby; Wei Xu; Jolie Ringash; Shaf Keshavjee; Eric Chen; Masoom Haider; Gail Darling Journal: Cancer Date: 2010-09-01 Impact factor: 6.860
Authors: Kim L Wang; Tsung-Teh Wu; In Seon Choi; Huamin Wang; Erika Resetkova; Erika Reseetkova; Arlene M Correa; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; Asif Rashid; Constance T Albarracin Journal: Cancer Date: 2007-02-15 Impact factor: 6.860
Authors: D H Ilson; L Saltz; P Enzinger; Y Huang; A Kornblith; M Gollub; E O'Reilly; G Schwartz; J DeGroff; G Gonzalez; D P Kelsen Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: Shu-lian Wang; Zhongxing Liao; Ara A Vaporciyan; Susan L Tucker; Helen Liu; Xiong Wei; Stephen Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-19 Impact factor: 7.038
Authors: Eunice L Kwak; Janusz Jankowski; Sarah P Thayer; Gregory Y Lauwers; Brian W Brannigan; Patricia L Harris; Ross A Okimoto; Sara M Haserlat; David R Driscoll; David Ferry; Beth Muir; Jeff Settleman; Charles S Fuchs; Matthew H Kulke; David P Ryan; Jeff W Clark; Dennis C Sgroi; Daniel A Haber; Daphne W Bell Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: Michael B Tomblyn; Bryan H Goldman; Charles R Thomas; Jacqueline K Benedetti; Heinz-Josef Lenz; Vivek Mehta; Thaddeus Beeker; Philip J Gold; James L Abbruzzese; Charles D Blanke Journal: J Thorac Oncol Date: 2012-05 Impact factor: 15.609
Authors: Howard Safran; Mohan Suntharalingam; Thomas Dipetrillo; Thomas Ng; L Austin Doyle; Mark Krasna; Angela Plette; Devon Evans; Harold Wanebo; Paul Akerman; Jeremy Spector; Nancy Kennedy; Teresa Kennedy Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-05 Impact factor: 7.038
Authors: David H Ilson; Manjit Bains; David P Kelsen; Eileen O'Reilly; Martin Karpeh; Daniel Coit; Valerie Rusch; Mithat Gonen; Katie Wilson; Bruce D Minsky Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: Shumei Song; Soichiro Honjo; Jiankang Jin; Shih-Shin Chang; Ailing W Scott; Qiongrong Chen; Neda Kalhor; Arlene M Correa; Wayne L Hofstetter; Constance T Albarracin; Tsung-Teh Wu; Randy L Johnson; Mien-Chie Hung; Jaffer A Ajani Journal: Clin Cancer Res Date: 2015-03-04 Impact factor: 12.531